Biosimilar cost savings yet to materialise, says healthcare organisation
Although the biosimilar market in the US is still early in development, US payers believe that the expected cost savings offer ed by biosimilar products have yet to materialise.
This is according to RG+A’s Health Payer Council, an online community of managed care pharmacy and medical directors.
The organisation said that biosimilars are likely to continue to face pricing pressure from innovator counterparts, and competition from other biosimilar products.
Enid McDonough, RG+A’s vice president for market access, said: “All payers are considering new, harder-edged strategies when debating coverage and management for biosimilar agents.”
He added: “This is particularly true of PBMs, which are drawing a hard line in the sand when determining coverage.”
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk